rheumatoid arthritis

3 Drug Catalysts to Watch in 2013

3 Drug Catalysts to Watch in 2013

Motley Fool

Enbrel's Asian Biosimilar Competitors

Enbrel's Asian Biosimilar Competitors

Seeking Alpha

Pfizer’s Arthritis Drug Rejected by European Regulators

Pfizer’s Arthritis Drug Rejected by European Regulators

Bloomberg

AZ arthritis drug may ease symptoms, but not progression

AZ arthritis drug may ease symptoms, but not progression

Delaware Online

AstraZeneca's Arthritis Drug Succeeds in Phase 3 Trial

AstraZeneca's Arthritis Drug Succeeds in Phase 3 Trial

Motley Fool

AstraZeneca, Rigel arthritis pill disappoints again

AstraZeneca, Rigel arthritis pill disappoints again

Reuters

Pfizer says XELJANZ approved in Japan for treatment of adults with RA

Pfizer says XELJANZ approved in Japan for treatment of adults with RA

Yahoo/Fly on the Wall

Taxpayer Funds, A Pfizer Drug And Big Profits

Taxpayer Funds, A Pfizer Drug And Big Profits

Pharmalot

Do These Pipeline Drugs Hold the Key to AbbVie's Future?

Do These Pipeline Drugs Hold the Key to AbbVie's Future?

Motley Fool

Merck's Weakest Blockbuster?

Merck's Weakest Blockbuster?

Motley Fool